Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe?
BACKGROUND
The use of hepatic arterial therapy (HAT) with either yttrium-90 or drug-eluting bead therapy for initially unresectable hepatic malignancies has risen significantly. The safety of hepatic resection after hepatic arterial therapy (HAT) is not established.


OBJECTIVE
The present study evaluates the safety profile for hepatic resection after HAT.


METHODS
We identified 840 patients undergoing hepatectomy for primary or metastatic lesions. Forty patients underwent HAT before hepatectomy (pre-HAT). A 1:4 case-matched analysis compared three groups: (i) pre-HAT and pre-operative chemotherapy (n=40); (ii) pre-operative chemotherapy (n=160); and (iii) no pre-operative therapy (n=640). Controls were matched for age, resection type, maximal tumour size and magnitude of resection. Morbidity and mortality among groups were compared using a graded complication scale.


RESULTS
There were no differences in post-operative complications, grade of complication or liver-specific complications among the groups. A proportional hazards model for all patients did not demonstrate any association between increased complications and either pre-HAT or pre-operative chemotherapy when compared with patients without pre-operative therapy (P=0.7).


CONCLUSIONS
Pre-HAT demonstrated similar morbidity, liver-specific morbidity and intra-operative complications when compared with patients undergoing pre-operative chemotherapy alone or without pre-operative chemotherapy. These results suggest that pre-HAT is safe and should not preclude hepatectomy in carefully selected patients.
Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY 40202, USA.
Russell E
RE
Brown
Matthew R
MR
Bower
Tiffany L
TL
Metzger
Charles R
CR
Scoggins
Kelly M
KM
McMasters
Michael J
MJ
Hahl
Cliff
C
Tatum
Robert C G
RC
Martin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000098:blood supply / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes
Oncology (Williston Park). 1994 Apr;8(4):77-84; discussion 84, 89-90 passim
8003400
J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2
12892803
World J Gastroenterol. 2010 Feb 28;16(8):927-33
20180230
J Clin Oncol. 2007 May 1;25(13):1753-9
17470865
J Surg Res. 2011 Apr;166(2):236-40
19691985
J Surg Oncol. 2006 Dec 1;94(7):572-86
17048240
Ann Surg. 2004 Aug;240(2):299-305
15273555
Ann Surg Oncol. 2009 Jan;16(1):35-41
18987915
J Oncol. 2009;2009:539795
19888427
Am Surg. 2011 Jan;77(1):93-8
21396314
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385